Parexel, n-Lorem Foundation to support investigational therapies for nano-rare patients
25 February 2022 | News
Parexel to provide clinical operations, real-world data solutions and expertise including medical and regulatory alongside innovative clinical research tools
Image credit: Shutterstock
Clinical research organisation Parexel has announced a new partnership with n-Lorem Foundation. The partnership aims to support of n-Lorem’s effort to discover and provide experimental antisense oligonucleotide (ASO) medicines to nano-rare disease patients (1 to 30 patients worldwide) for free, for life.
Parexel brings significant expertise to the partnership, having managed approximately 400 rare disease clinical studies over the past five years that contributed to 17 FDA drug approvals.
Stanley T Crooke, Founder, CEO and Chairman, n-Lorem Foundation said, “Parexel will provide the necessary systems to assure that each patient’s natural history and clinical studies are well managed, which will be very important as we accept more nano-rare patients and collect data that informs our future decisions and aggregate experience.”
